Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 2,508 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Normal protein Clear all

Conditions: Refractory Multiple Myeloma
Interventions: fludarabine phosphate, melphalan, total-body irradiation, mycophenolate mofetil, cyclosporine, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis; Drug · Radiation · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: T-cell Non-Hodgkin Lymphoma
Interventions: Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, Prednisone, Filgrastim, Plerixafor, Stem Cell Collection, Palifermin, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Allopurinol, Carmustine, Etoposide, Cytarabine, Melphalan; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Kallmann Syndrome, Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions: gonadotropin releasing hormone (GnRH); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Castration Sensitive Prostate Cancer
Interventions: Luteinizing Hormone-Releasing Hormone (LHRH) analog, Androgen Receptor Signal Inhibitor (ARSI), Docetaxel; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: MelanomaCutaneous Melanoma Resectable, Melanoma
Interventions: RP2 (vusolimogene oderparepvec), Nivolumab, Definitive Surgical Resection; Drug · Procedure
Lead sponsor: Yana Najjar; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: filgrastim, anastrozole, carboplatin, cisplatin, cyclophosphamide, etoposide, thiotepa, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: filgrastim, amifostine trihydrate, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 59 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2023
U.S. locations: 1
States / cities: Duarte, California

Conditions: Renal Pelvis and Ureter Urothelial Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Pegfilgrastim, Therapeutic Conventional Surgery, Vinblastine Sulfate; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 258
States / cities: Kingman, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 197 more

Conditions: Obesity, Infertility, Hypogonadotropic Hypogonadotropism, Hyperinsulinemia
Interventions: Insulin, Intralipid, Dextrose, Heparin, GnRH, Hyperinsulinemic Euglycemic Clamp; Drug · Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Myocardial Infarction
Interventions: Tenecteplase, PCI; Drug · Procedure
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 8
States / cities: Little Rock, Arkansas • Fort Lauderdale, Florida • St. Petersburg, Florida + 5 more

Conditions: Forehead Rhytides, Glabellar Rhytides
Interventions: OnabotulinumtoxinA, Normal Saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: Birmingham, Alabama • Glendale, Arizona • Santa Monica, California + 6 more

Conditions: Alzheimer's Disease
Interventions: 18F-THK-5351, Lumbar Puncture (optional); Drug · Procedure
Lead sponsor: William Charles Kreisl; Other
Eligibility: 50 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Tissue Expander (TE), Vancomycin and Gentamicin, Stimulan Rapid Cure; Procedure · Drug · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses
Interventions: Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), Surgical gauze pads; Biological · Other
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: Not listed
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 22
States / cities: Birmingham, Alabama • Tucson, Arizona • Fresno, California + 19 more

Conditions: Sarcoma, Leiomyosarcoma, Malignant Fibrous, Histiocytoma, Angiosarcoma
Interventions: gemcitabine, docetaxel, bevacizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiac Surgery-CABG, Cardiac Valve Replacement
Interventions: Epogen, Normal Saline; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: etoposide, ifosfamide, intensity-modulated radiation therapy, topotecan hydrochloride, busulfan, melphalan, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, autologous bone marrow transplantation; Drug · Radiation · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 6 Months to 40 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Duarte, California

Conditions: Healthy Volunteers
Interventions: Testosterone, Goserelin acetate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years to 75 Years · Male only
Enrollment: 177 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Menopause
Interventions: ACTH; Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
Interventions: Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 40 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Healthy
Interventions: Lyophilized Plasma, Fresh Frozen Plasma; Biological · Other
Lead sponsor: HemCon Medical Technologies, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chronic Myeloproliferative Disorders
Interventions: filgrastim, busulfan, cytarabine, idarubicin, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 7
States / cities: Anchorage, Alaska • Tampa, Florida • Chicago, Illinois + 4 more

Conditions: Mesothelioma
Interventions: Pleurectomy/Decortication, pemetrexed and cisplatin or carboplatin, Intensity Modulated Radiation Therapy; Procedure · Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 12
States / cities: Tampa, Florida • Boston, Massachusetts • Rochester, Minnesota + 9 more

Search by objective public record fields.

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Neoadjuvant RP2 + Nivolumab in Patients With Melanoma

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Reprometabolic Syndrome Mediates Subfertility in Obesity

A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)

A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides

Imaging Tau in Alzheimer's Disease and Normal Aging

A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement

FS VH S/D 500 S-apr in Vascular Surgery

Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma

Dose-Response of Gonadal Steroids and Bone Turnover in Older Men

Cortisol Levels on Menopausal Symptoms - Ancillary (Addendum) Study to Protocol 16997

Autonomic and Renal Contributions to Hypertension With ADT

The Safety of Autologous Lyophilized Plasma Versus Fresh Frozen Plasma in Healthy Volunteers

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis

Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma